- **Sunshine Biopharma's subsidiary, Nora Pharma, has received Health Canada approval to commercialize Domperidone**, a prescription drug used to treat nausea and vomiting, marking its entry into the Canadian pharmaceutical market.  **[1402328_4b7ce9fdcf864387ab4fcca172d78761]** 
- The **North American Domperidone market is projected to reach $533 million in 2025**.  **[1402328_4b7ce9fdcf864387ab4fcca172d78761]** 
- The company currently has **76 generic prescription drugs in Canada** and plans to launch more than 12 additional drugs in 2026.  **[1402328_4b7ce9fdcf864387ab4fcca172d78761]** 
- Financially, Sunshine Biopharma has a **market capitalization around $9.6 million**, faces **negative earnings**, and has an **Altman Z-Score of -0.93**, indicating distress and potential bankruptcy risk within two years.  **[1402328_4b7ce9fdcf864387ab4fcca172d78761]** 
- **Insider ownership is significant at 24.07%**, reflecting confidence in the company's strategic direction despite low institutional ownership.  **[1402328_4b7ce9fdcf864387ab4fcca172d78761]**

Sunshine Biopharma (SBFM)